Role of the chemokine receptors CXCR3 and CCR4 in human pulmonary fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 173, Issue 3, 2006, Pages 310-317

  Pignatti, Patrizia ^b   Brunetti, Giuseppe ^a   Moretto, Dania ^b   Yacoub, Mona Rita ^b   Fiori, Marco ^b   Balbi, Bruno ^b   Balestrino, Antonella ^b   Cervio, Gabriella ^b   Nava, Stefano ^b   Moscato, Gianna ^b  

^a IRCCS   (Italy)

^b NONE

Author keywords

Chemokines; CXCL10; Interstitial lung diseases

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CORTICOSTEROID; CXCL11 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; EOSINOPHIL; FEMALE; FLOW CYTOMETRY; HUMAN; IDIOPATHIC DISEASE; IMMUNOASSAY; LUNG ALVEOLUS OXYGEN TENSION; LUNG FIBROSIS; LUNG LAVAGE; MALE; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SARCOIDOSIS; T LYMPHOCYTE; TOTAL LUNG CAPACITY; VITAL CAPACITY;

ADULT; AGED; BRONCHOALVEOLAR LAVAGE FLUID; CASE-CONTROL STUDIES; CHEMOKINES, CC; CHEMOKINES, CXC; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY FIBROSIS; RECEPTORS, CHEMOKINE; SARCOIDOSIS, PULMONARY; T-LYMPHOCYTES;

EID: 32144452037     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200502-244OC     Document Type: Article

References (46)

1. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001;345:517-525.
2. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994;150:967-972.
3. Gauldie J. Inflammatory mechanisms are a minor component of the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002;165:1205-1206.
4. Gauldie J, Kolb M, Sime PJ. A new direction in the pathogenesis of idiopathic pulmonary fibrosis? Respir Res 2002;3:1-3.
5. Agostini C, Siviero M, Semenzato G. Immune effector cells in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 1997;3:348-355.
6. Coker RK, Laurent GJ. Pulmonary fibrosis: cytokines in balance. Eur Respir J 1998;11:1218-1221.
7. D'Ambrosio D, Mariani M, Panina-Bordignon P, Sinigaglia F. Chemokines and their receptors guiding T lymphocyte recruitment in lung inflammation. Am J Respir Crit Care Med 2001;164:1266-1275.
8. Campbell JJ, Brightling CE, Symon FA, Qin S, Murphy KE, Hodge M, Andrew DP, Wu L, Butcher EC, Wardlaw AJ. Expression of chemokine receptors by lung T cells from normal and asthmatic subjects. J Immunol 2001;166:2842-2848.
9. Panina-Bordignon P, Papi A, Mariani M, Di Lucia P, Casoni G, Bellettato C, Buonsanti C, Miotto D, Mapp C, Villa A, et al. The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. J Clin Invest 2001;107:1357-1364.
10. Saetta M, Mariani M, Panina-Bordignon P, Turato G, Buonsanti C, Baraldo S, Bellettato CM, Papi A, Corbetta L, Zuin R, et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;165:1404-1409.
11. Agostini C, Cassatella M, Zambello R, Trentin L, Gasperini S, Perin A, Piazza F, Siviero M, Facco M, Dziejman M, et al. Involvement of the CXCL10 chemokine in sarcoid granulomatous reactions. J Immunol 1998;161:6413-6420.
12. Katoh S, Fukushima K, Matsumoto N, Matsumoto K, Abe K, Onai N, Matsushima K, Matsukura S. Accumulation of CCR4-expressing CD4+ T cells and high concentration of its ligands (TARC and MDC) in bronchoalveolar lavage fluid of patients with eosinophilic pneumonia. Allergy 2003;58:518-523.
13. Shimizu S, Yoshinouchi T, Naniwa T, Nakamura M, Sato S, Ohtsuki Y, Fujita J, Yamadori I, Eimoto T, Ueda R. Distribution of CXCR3- or CCR4-positive cells in interstitial pneumonia associated with primary Sjogren's syndrome. Virchows Arch 2004;445:477-484.
14. Jiang D, Liang J, Hodge J, Lu B, Zhu Z, Yu S, Fan J, Gao Y, Yin Z, Homer R, et al. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J Clin Invest 2004;114:291-299.
15. Burdick MD, Murray LA, Keane MP, Xue YY, Zisman DA, Belperio JA, Stieter RM. CXCL11 attenuates bleomycin induced pulmonary fibrosis via inhibition of vascular remodeling. Am J Respir Crit Care Med 2005;171:261-268.
16. Tager AM, Kradin RL, LaCamera P, Bercury SD, Campanella GSV, Leary CP, Polosukhin V, Tzao LH, Sakamoto H, Blackwell TS, et al. Inhibition of pulmonary fibrosis by the chemokine CXCL10/CXCL10. Am J Respir Cell Mol Biol 2004;31:395-404.
17. Belperio JA, Dy M, Murray L, Burdick MD, Xue YY, Strieter RM, Keane MP. The role of the Th2 CC chemokine ligand CCL17 in pulmonary fibrosis. J Immunol 2004;173:4692-4698.
18. Pignatti P, Moscato G, Yacoub M-R, Fiori M, Balbi B, Balestrino A, Cervio G, Nava S, Brunetti G. The expression of the chemokine receptors CXCR3 and CCR4 on T cells re.ects the Th2 switch in the bronchoalveolar lavage (BAL) of idiopathic pulmonary fibrosis patients. Eur Respir J 2004;24:11s.
19. American Thoracic Society/European Respiratory Society. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277-304.
20. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-590.
21. American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med 2004;170:691-715.
22. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160:736-755.
23. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Eur Respir J 1993;6:15-40.
24. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC. Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993;6:41-52.
25. American Thoracic Society. ATS statement: guidelines for the 6-minute walk test. Am J Respir Crit Care Med 2002;166:111-117.
26. Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, Cascade PN, Whyte RI, Lynch JP III, Toews G. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997;169:977-983.
27. European Society of Pneumology Task Group. Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Report of the European Society of Pneumology Task Group. Eur Respir J 1989;2:561-585.
28. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-151.
29. Whyte MKB. Genetic factors in idiopathic pulmonary fibrosis: transforming growth factor-β implicated at last. Am J Respir Crit Care Med 2003;168:410-411.
30. Wallace WA, Ramage EA, Lamb D, Howie SE. A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA). Clin Exp Immunol 1995;101:436-441.
31. Furuie H, Yamasaki H, Suga M, Ando M. Altered accessory cell function of alveolar macrophages: a possible mechanism for induction of Th2 secretory profile in idiopathic pulmonary fibrosis. Eur Respir J 1997;10:787-794.
32. Prior C, Haslam PL. In vivo levels and in vitro production of interferon-gamma in fibrosing interstitial lung diseases. Clin Exp Immunol 1992;88:280-287.
33. Majumdar S, Li D, Ansari T, Pantelidis P, Black CM, Gizycki M, du Bois RM, Jeffery PK. Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies. Eur Respir J 1999;14:251-257.
34. Postlethwaite AE, Holness MA, Katai H, Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992;90:1479-1485.
35. Postlethwaite AE, Seyer JM. Fibroblast chemotaxis induction by human recombinant interleukin-4. Identification by synthetic peptide analysis of two chemotactic domains residing in amino acid sequences 70-88 and 89-122. J Clin Invest 1991;87:2147-2152.
36. Kim CH, Rott L, Kunkel EJ, Genovese MC, Andrew DP, Wu L, Butcher EC. Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest 2001;108:1331-1339.
37. Kurashima K, Fujimura M, Myou S, Kasahara K, Tachibana H, Amemiya N, Ishiura Y, Onai N, Matsushima K, Nakao S. Effects of oral steroids on blood CXCR3+ and CCR4+ T cells in patients with bronchial asthma. Am J Respir Crit Care Med 2001;164:754-758.
38. Robinson D, Hamid Q, Ying S, Bentley A, Assoufi B, Durham S, Kay AB. Prednisolone treatment in asthma is associated with modulation of bronchoalveolar lavage cell interleukin-4, interleukin-5, and interferon-gamma cytokine gene expression. Am Rev Respir Dis 1993;148:401-406.
39. Luppi F, Cerri S, Beghe B, Fabbri LM, Richeldi L. Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis. Respir Med 2004;98:1035-1044.
40. Egan JJ, Martinez FJ, Wells AU, Williams T. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax 2005;60:270-273.
41. Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, Veeraraghavan S, Hansell DM, Wells AU. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003;168:531-537.
42. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiological variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-542.
43. Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, Toews GB, Lynch JP III, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:543-548.
44. Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S. CXC chemokines; the regulatory link between inflammation and angiogenesis. Trends Immunol 2004;25:201-209.
45. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, et al. An alternative spliced variant of CXCR3 mediates the IP-10, Mig and I-TAC induced inhibition of endothelial cell growth and acts as functional receptor for PF-4. J Exp Med 2003;197:1537-1549.
46. Turner-Warwick M. Precapillary systemic-pulmonary anastomoses. Thorax 1963;18:225-237.